As of Jan 17, 2025, Johnson & Johnson's Discounted Cash Flow (DCF) valuation estimates its share price at $229.1. This suggests it may be undervalued by 55.8% compared to its current price of around $147.0, using a WACC of 7.2% and growth rates of 3.0%.
As of Jan 17, 2025, Johnson & Johnson's Weighted Average Cost of Capital (WACC) is approximately 7.2%.
As of Jan 17, 2025, Johnson & Johnson's Enterprise Value (EV) is approximately $559.0B. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.